The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy

European Urology

Volumn 62, Issue 1, 2012, Pages 88-96

  Audet Walsh, Étienne ^a   Bellemare, Judith ^a   Lacombe, Louis ^b   Fradet, Yves ^b   Fradet, Vincent ^b   Douville, Pierre ^b   Guillemette, Chantal ^a   Lévesque, Éric ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b Université Laval   (Canada)

Author keywords

17 HSD genes; Biochemical recurrence; Germline polymorphisms; HSD17B12; HSD17B2; HSD17B3; Prostate cancer; Prostate cancer progression

Indexed keywords

HYDROXYSTEROID DEHYDROGENASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CAUCASIAN; DISEASE ASSOCIATION; ETHNIC GROUP; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; GERMLINE MICRONUCLEUS; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

17-HYDROXYSTEROID DEHYDROGENASES; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SPERMATOZOA; TREATMENT OUTCOME;

EID: 84861628092     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.12.021     Document Type: Article

References (29)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2011 277 300
2. A.V D'Amico, R. Whittington, and S.B. Malkowicz Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials J Clin Oncol 18 2000 3240 3246
3. G.P. Swanson, C. Yu, M.W. Kattan, and M.R. Hermans Validation of postoperative nomograms in prostate cancer patients with long-term follow-up Urology 78 2011 105 109
4. J. Ahn, A.S. Kibel, and J.Y. Park Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence Clin Cancer Res 17 2011 1075 1081
5. F.E. Wiklund, H.O. Adami, and S.L. Zheng Established prostate cancer susceptibility variants are not associated with disease outcome Cancer Epidemiol Biomarkers Prev 18 2009 1659 1662
6. W.P. Harris, E.A. Mostaghel, P.S. Nelson, and B. Montgomery Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion Nat Clin Pract Urol 6 2009 76 85
7. E.M. Horwitz Prostate cancer: optimizing the duration of androgen deprivation therapy Nat Rev Urol 6 2009 527 529
8. I.M. Thompson, P.J. Goodman, and C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215 224
9. G.L. Andriole, D.G. Bostwick, and O.W. Brawley Effect of dutasteride on the risk of prostate cancer N Engl J Med 362 2010 1192 1202
10. E. Audet-Walsh, J. Bellemare, and G. Nadeau SRD5A polymorphisms and biochemical failure after radical prostatectomy Eur Urol 60 2011 1226 1234
11. V. Luu-The, and F. Labrie The intracrine sex steroid biosynthesis pathways Prog Brain Res 181 2010 177 192
12. F. Labrie, V. Luu-The, and S.X. Lin Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease J Mol Endocrinol 25 2000 1 16
13. W.M. Geissler, D.L. Davis, and L. Wu Male pseudohermaphroditism caused by mutations of testicular 17 beta-hydroxysteroid dehydrogenase 3 Nat Genet 7 1994 34 39
14. P. Kraft, P. Pharoah, and S.J. Chanock Genetic variation in the HSD17B1 gene and risk of prostate cancer PLoS Genet 1 2005 e68
15. K.K. Rasiah, M. Gardiner-Garden, and E.J. Padilla HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer Mol Cell Endocrinol 301 2009 89 96
16. R.W. Ross, W.K. Oh, and W. Xie Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer J Clin Oncol 26 2008 842 847
17. E. Koh, T. Noda, J. Kanaya, and M. Namiki Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues Prostate 53 2002 154 159
18. Y. Takase, M.H. Levesque, V. Luu-The, M. El-Alfy, F. Labrie, and G. Pelletier Expression of enzymes involved in estrogen metabolism in human prostate J Histochem Cytochem 54 2006 911 921
19. M. Stephens, N.J. Smith, and P. Donnelly A new statistical method for haplotype reconstruction from population data Am J Hum Genet. 68 2001 978 989
20. C.L. Amling, E.J. Bergstralh, M.L. Blute, J.M. Slezak, and H. Zincke Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 165 2001 1146 1151
21. M.E. Nielsen, and A.W. Partin The impact of definitions of failure on the interpretation of biochemical recurrence following treatment of clinically localized prostate cancer Rev Urol 9 2007 57 62
22. J.D. Storey, and R. Tibshirani Statistical significance for genomewide studies Proc Natl Acad Sci U S A 100 2003 9440 9445
23. G. Lughezzani, L. Budäus, and H. Isbarn Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy Eur Urol 57 2010 562 568
24. M. Yang, W. Xie, and E. Mostaghel SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer J Clin Oncol 29 2011 2565 2573
25. P. Harkonen, A.P. Kyllonen, S. Nordling, and P. Vihko Loss of heterozygosity in chromosomal region 16q24.3 associated with progression of prostate cancer Prostate 62 2005 267 274
26. J.P. Elo, P. Harkonen, and A.P. Kyllonen Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer Cancer Res 57 1997 3356 3359
27. J.P. Elo, P. Harkonen, A.P. Kyllonen, O. Lukkarinen, and P. Vihko Three independently deleted regions at chromosome arm 16q in human prostate cancer: allelic loss at 16q24.1-q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumour and poor prognosis for the patient Br J Cancer 79 1999 156 160
28. J.P. Elo, L.A. Akinola, and M. Poutanen Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate Int J Cancer 66 1996 37 41
29. P. Harkonen, S. Torn, and R. Kurkela Sex hormone metabolism in prostate cancer cells during transition to an androgen-independent state J Clin Endocrinol Metab 88 2003 705 712